Validation of an RNA cell cycle progression score for predicting death from prostate cancer in a conservatively managed needle biopsy cohort

British Journal of Cancer

Volumn 113, Issue 3, 2015, Pages 382-389

  Cuzick, J ^a   Stone, S ^b   Fisher, G ^a   Yang, Z H ^a   North, B V ^a   Berney, D M ^a   Beltran, L ^a   Greenberg, D ^c   Moller H ^d   Reid, J E ^b   Gutin, A ^b   Lanchbury, J S ^b   Brawer, M ^b   Scardino, P ^e  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b Utah   (United States)

^c PUBLIC HEALTH ENGLAND   (United Kingdom)

^d KING'S COLLEGE LONDON   (United Kingdom)

^e MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; RNA;

ADULT; AGE; AGED; ARTICLE; CANCER GRADING; CANCER MORTALITY; CANCER OF THE PROSTATE RISK ASSESSMENT; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CELL CYCLE PROGRESSION SCORE; CLINICAL CELL CYCLE RISK SCORE; CLINICAL FEATURE; COHORT ANALYSIS; CONSERVATIVE TREATMENT; CONTROLLED STUDY; GENITAL SYSTEM DISEASE ASSESSMENT; GLEASON SCORE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; NEEDLE BIOPSY; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSTIC ASSESSMENT; PROSTATE CANCER; PROSTATECTOMY; RETROSPECTIVE STUDY; RISK ASSESSMENT; SCORING SYSTEM; UNITED KINGDOM; VALIDATION STUDY; BLOOD; CELL CYCLE; DISEASE COURSE; FOLLOW UP; GENETICS; METHODOLOGY; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; PROSTATIC NEOPLASMS;

ADULT; AGED; BIOPSY, NEEDLE; CELL CYCLE; COHORT STUDIES; DISEASE PROGRESSION; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; PROGNOSIS; PROSTATIC NEOPLASMS; RESEARCH DESIGN; RNA;

EID: 84938417741     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2015.223     Document Type: Article

References (27)

1. Albertsen JL, Hanley JA, Gleason DF, Barry MJ (1998) Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer. JAMA 280: 975-980.
2. Albertsen PC, Hanley JA, Fine J (2005) 20-year outcomes following conservative management of clinically localized prostate cancer. JAMA 293(17): 2095-2101.
3. Andriole GL, Crawford ED, Grubb 3rd RL, Buys SS, Chia D, Church TR, Fouad MN, Gelmann EP, Kvale PA, Reding DJ, Weissfeld JL, Yokochi LA, O'Brien B, Clapp JD, Rathmell JM, Riley TL, Hayes RB, Kramer BS, Izmirlian G, Miller AB, Pinsky PF, Prorok PC, Gohagan JK, Berg CD. PLCO Project Team (2009) Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 360(13): 1310-1319.
4. Bishoff JT, Freedland SJ, Gerber L, Tennstedt P, Reid J, Welbourn W, Graefen M, Sangale Z, Tikishvili E, Park J, Younus A, Gutin A, Lanchbury JS, Sauter G, Brawer M, Stone S, Schlomm T (2014) Prognostic utility of the CCP score generated from biopsy in men treated with prostatectomy. J Urol 192(2): 409-414.
5. Brawer MK, Cooperberg MR, Freedland SJ, Swanson GP, Stone S, Reid JE, Gutin A, Carroll P, Cuzick JM (2013) Development and validation of a multivariate model combining cell cycle progression score with CAPRA to predict prostate cancer mortality in a conservatively managed cohort. J Clin Oncol 31: 6s (suppl; abstr 67).
6. Cooperberg MR, Pasta DJ, Elkin EP, Litwin MS, Latini DM, Du Chane J, Carroll PR (2005) The University of California, San Francisco Cancer of the Prostate Risk Assessment score: a straightforward and reliable preoperative predictor of disease recurrence after radical prostatectomy. J Urol 173(6): 1938-1942.
7. Cooperberg MR, Freedland SJ, Pasta DJ, Elkin EP, Presti Jr JC, Amling CL, Terris MK, Aronson WJ, Kane CJ, Carroll PR (2006) Multi-institutional validation of the UCSF cancer of the prostate risk assessment for prediction of recurrence after radical prostatectomy. Cancer 107(10): 2384-2391.
8. Cooperberg MR, Broering JM, Carroll PR (2009) Risk assessment for prostate cancer metastasis and mortality at the time of diagnosis. J Natl Cancer Inst 101: 878-887.
9. Cooperberg MR, Carroll PR, Klotz L (2011) Active surveillance for prostate cancer: progress and promise. J Clin Oncol 29: 3669-3676.
10. Cooperberg MR, Simko JP, Cowan JE, Reid JE, Djalilvand A, Bhatnagar S, Gutin A, Lanchbury JS, Swanson GP, Stone S, Carroll PR (2013) Validation of a cell-cycle progression gene panel to improve risk stratification in a contemporary prostatectomy cohort. J Clin Oncol 31(11): 1428-1434.
11. Cuzick J, Fisher G, Kattan MW, Berney D, Oliver T, Foster CS, Møller H, Reuter V, Fearn P, Eastham J, Scardino P. Transatlantic Prostate Group (2006) Long-term outcome among men with conservatively treated localised prostate cancer. Br J Cancer 95: 1186-1194.
12. Cuzick J, Swanson GP, Fisher G, Brothman AR, Berney DM, Reid JE, Mesher D, Speights VO, Stankiewicz E, Foster CS, Møller H, Scardino P, Warren JD, Park J, Younus A, Flake 2nd DD, Wagner S, Gutin A, Lanchbury JS, Stone S. Transatlantic Prostate Group (2011) Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective study. Lancet Oncol 12(3): 245-255.
13. Cuzick J, Berney DM, Fisher G, Mesher D, Møller H, Reid JE, Perry M, Park J, Younus A, Gutin A, Foster CS, Scardino P, Lanchbury JS, Stone S. Transatlantic Prostate Group (2012) Prognostic value of a cell cycle progression signature for prostate cancer death in a conservatively managed needle biopsy cohort. Br J Cancer 106: 1095-1099.
14. Cuzick J, Thorat MA, Andriole G, Brawley OW, Brown PH, Culig Z, Eeles RA, Ford LG, Hamdy FC, Holmberg L, Ilic D, Key TJ, La Vecchia C, Lilja H, Marberger M, Meyskens FL, Minasian LM, Parker C, Parnes HL, Perner S, Rittenhouse H, Schalken J, Schmid HP, Schmitz-Dräger BJ, Schröder FH, Stenzl A, Tombal B, Wilt TJ, Wolk A (2014) Prevention and early detection of prostate cancer. Lancet Oncol 15(11): e484-e492.
15. Dall'Era MA, Albertsen PC, Bangma C, Carroll PR, Carter HB, Cooperberg MR, Freedland SJ, Klotz LH, Parker C, Soloway MS (2012) Active surveillance for prostate cancer: a systematic review of the literature. Eur Urol 62: 976-983.
16. Epstein JI, Allsbrook Jr WC, Amin MB, Egevad LL. ISUP Grading Committee (2005) The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma. Am J Surg Pathol 29(9): 1228-1242.
17. Epstein JI (2010) An update of the Gleason grading system. J Urol 183(2): 433-440.
18. Freedland SJ, Gerber L, Reid J, Welbourn W, Tikishvili E, Park J, Younus A, Gutin A, Sangale Z, Lanchbury JS, Salama JK, Stone S (2013) Prognostic utility of cell cycle progression score in men with prostate cancer after primary external beam radiation therapy. Int J Radiat Oncol Biol Phys 86(5): 848-853.
19. Kattan MW, Cuzick J, Fisher G, Berney DM, Oliver T, Foster CS, Møller H, Reuter V, Fearn P, Eastham J, Scardino PT. Transatlantic Prostate Group (2008) Nomogram incorporating PSA level to predict cancer-specific survival for men with clinically localized prostate cancer managed without curative intent. Cancer 112(1): 69-74.
20. Lalonde E, Ishkanian AS, Sykes J, Fraser M, Ross-Adams H, Erho N, Dunning MJ, Halim S, Lamb AD, Moon NC, Zafarana G, Warren AY, Meng X, Thoms J, Grzadkowski MR, Berlin A, Have CL, Ramnarine VR, Yao CQ, Malloff CA, Lam LL, Xie H, Harding NJ, Mak DY, Chu KC, Chong LC, Sendorek DH, P'ng C, Collins CC, Squire JA, Jurisica I, Cooper C, Eeles R, Pintilie M, Dal Pra A, Davicioni E, Lam WL, Milosevic M, Neal DE, van der Kwast T, Boutros PC, Bristow RG (2014) Tumour genomic and microenvironmental heterogeneity for integrated prediction of 5-year biochemical recurrence of prostate cancer: a retrospective cohort study. Lancet Oncol 15(13): 1521-1532.
21. May M, Knoll N, Siegsmund M, Fahlenkamp D, Vogler H, Hoschke B, Gralla O (2007) Validity of the CAPRA score to predict biochemical recurrence-free survival after radical prostatectomy. Results from a European multicenter survey of 1, 296 patients. J Urol 178(5): 1957-1962.
22. Moyer VA. U.S. Preventive Services Task Force (2012) Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 157(2): 120-134.
23. Schröder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, Kwiatkowski M, Lujan M, Lilja H, Zappa M, Denis LJ, Recker F, Páez A, Määttänen L, Bangma CH, Aus G, Carlsson S, Villers A, Rebillard X, van der Kwast T, Kujala PM, Blijenberg BG, Stenman UH, Huber A, Taari K, Hakama M, Moss SM, de Koning HJ, Auvinen A. ERSPC Investigators (2012) Prostate-cancer mortality at 11 years of follow-up. N Engl J Med 366(11): 981-990
24. Erratum in: N Engl J Med May 31;366(22):2137.
25. Sommariva S, Tarricone R, Lazzeri M, Ricciardi W, Montorsi F (2014) Prognostic value of the cell cycle progression score in patients with prostate cancer: a systematic review and meta-analysis. Eur Urol; e-pub ahead of print 4 December 2014; doi:10.1016/j.eururo.2014.11.038.
26. WHO (2010) International statistical classification of diseases and related health problems. 10th revision, 4th edition ISBN 978 92 4 154834 2. http://www.who.int/classifications/icd/ICD10Volume2-en-2010.pdf.
27. Zhao KH, Hernandez DJ, Han M, Humphreys EB, Mangold LA, Partin AW (2008) External validation of University of California, San Francisco, Cancer of the Prostate Risk Assessment score. Urology 72(2): 396-400.